ArticleFrontiers in medicine2026
Effects of meropenem plus ulinastatin on inflammatory response and complications in patients with severe septic shock.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To evaluate whether receipt of ulinastatin in addition to meropenem-based standard care was associated with inflammatory, coagulation, perfusion, and clinical outcomes in patients with severe septic shock. Methods: This single-center retrospective, non-randomized comparative cohort study included 106 consecutive patients with severe septic shock treated between January 2023 and November 2025. Patients were classified according to treatment received in routine clinical practice: meropenem-based standard care plus ulinastatin (observation group, Results: The overall response rate in the observation group presented higher at 90.6% (48/53) versus 73.6% (39/53) in the control group ( Conclusion: In this single-center retrospective cohort, receipt of ulinastatin in addition to meropenem-based standard care was associated with more favorable inflammatory, coagulation, lactate-clearance, hemodynamic, immune, and resource-use outcomes. Because treatment was not randomized and residual confounding cannot be excluded, these findings should not be interpreted as proof of causality or synergy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.